Alkem Becomes First Indian Company To Launch Novel Antibiotic For Multiple Drug Resistance (MDR) Infections The available evidence suggests that Zidavi is a potential therapeutic option for the treatment of infections complicated by multi-drug resistant (MDR) organisms

By Teena Jose

Opinions expressed by Entrepreneur contributors are their own.

You're reading Entrepreneur India, an international franchise of Entrepreneur Media.

Pexels

Alkem (Intenza, critical care division) has announced the launch of its novel anti-infective in India under the brand name Zidavi. This is in line with company's endeavour to ensure affordability, accessibility, and availability while saving the lives of critically ill patients.

Zidavi, which is a novel combination of ceftazidime and avibactam, is recommended by the infectious disease society of America (IDSA) and the Indian council of medical research (ICMR) as a preferred treatment against OXA-48-like and Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant Enterobacteriaceae (CRE) for pyelonephritis or complicated urinary tract infections (cUTI) and in other CRE infections caused by KPC and OXA-48 producers.

"With the launch of Zidavi, our aim is to ensure that Alkem continues to remain at the forefront while partnering with clinicians for saving lives," said company spokesperson.

With the rise in infections caused by carbapenem-resistant Gram-negative organisms in India, there is a need for more effective antibiotic treatment. The available evidence suggests that Zidavi (ceftazidime-avibactam) is a potential therapeutic option for the treatment of infections complicated by multi-drug resistant (MDR) organisms. Zidavi 2.5g (ceftazidime and avibactam) for infusion is available as a sterile powdered concentrate for reconstitution. Each single-dose vial contains ceftazidime pentahydrate equivalent to 2g ceftazidime and avibactam sodium equivalent to 0.5g avibactam. It is available at an affordable price of INR 2,700/vial. Zidavi's strength lies in its indigenously developed (Active Pharmaceutical Ingredients) API, which is manufactured in the company's state-of-the-art manufacturing plant in Sikkim, the statement added, according to statement given by the company.

Alkem is a leading Indian global pharmaceutical company that manufactures and markets bio-similars and pharmaceutical formulations in India and across the globe.
Teena Jose

News Desk Reporter with Entrepreneur India

Teena is a post graduate in financial journalism. She has an avid interest in content creation, digital media and fashion.
Business News

JPMorgan Shuts Down Internal Message Board Comments After Employees React to Return-to-Office Mandate

Employees were given the option to leave comments about the RTO mandate with their first and last names on display — and they did not hold back.

Business Ideas

70 Small Business Ideas to Start in 2025

We put together a list of the best, most profitable small business ideas for entrepreneurs to pursue in 2025.

News and Trends

Recur Club Announces Credit Offerings for Startups Beyond Series A and SMEs

In FY 24–25, the platform also plans to deploy an additional INR 2000 crores through its Recur Swift program for startups.

News and Trends

NeoSapien Secures INR 80 Lakhs on Shark Tank India 4 for AI Wearable

Founded in 2024 by Dhananjay Yadav and Aryan Yadav, NeoSapien aims to integrate AI into daily life through its wearable technology

News and Trends

PAG Acquires Majority Stake in Pharma Packaging Player Pravesha Industries

This move underscores PAG's continued focus on India's burgeoning packaging industry, following its recent investment in Manjushree Technopack.

Leadership

From Elite Athletes to Tech Titans — Discover the Surprising $100-Million Habit That Leads to Extraordinary Success

Success comes from mastering focus, eliminating distractions and prioritizing what truly matters.